📣 VC round data is live. Check it out!
- Public Comps
- Genetic Technologies
Genetic Technologies Valuation Multiples
Discover revenue and EBITDA valuation multiples for Genetic Technologies and similar public comparables like Strategic Partners, Geovax Labs, Opthea, Akari Therapeutics and more.
Genetic Technologies Overview
About Genetic Technologies
Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.
Founded
1987
HQ

Employees
58
Website
Financials (FY)
EV
$4M
Valuation Multiples
Start free trialGenetic Technologies Financials
Genetic Technologies reported last fiscal year revenue of $6M and negative EBITDA of ($8M).
In the same fiscal year, Genetic Technologies generated $3M in gross profit, ($8M) in EBITDA losses, and had net loss of ($9M).
Revenue (LTM)
Genetic Technologies P&L
In the most recent fiscal year, Genetic Technologies reported revenue of $6M and EBITDA of ($8M).
Genetic Technologies is unprofitable as of last fiscal year, with gross margin of 51%, EBITDA margin of (149%), and net margin of (157%).
Financial data powered by Morningstar, Inc.
Genetic Technologies Stock Performance
Genetic Technologies has current market cap of $4M, and enterprise value of $4M.
Market Cap Evolution
Genetic Technologies' stock price is $0.03.
Genetic Technologies has an EPS (earnings per share) of $-0.06.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4M | $4M | -0.4% | — | — | — | $-0.06 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGenetic Technologies Valuation Multiples
Genetic Technologies trades at 0.7x EV/Revenue multiple, and (0.5x) EV/EBITDA.
EV / Revenue (LTM)
Genetic Technologies Financial Valuation Multiples
As of May 14, 2026, Genetic Technologies has market cap of $4M and EV of $4M.
Genetic Technologies has a P/E ratio of (0.5x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Genetic Technologies Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Genetic Technologies Margins & Growth Rates
In the most recent fiscal year, Genetic Technologies reported gross margin of 51%, EBITDA margin of (149%), and net margin of (157%).
Genetic Technologies Margins
Genetic Technologies Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Genetic Technologies Operational KPIs
Genetic Technologies' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.2M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Genetic Technologies Competitors
Genetic Technologies competitors include Strategic Partners, Geovax Labs, Opthea, Akari Therapeutics, Reviva Pharmaceuticals, JFL Life Sciences, Newbury Pharmaceuticals, Institute of Biomedical, Abattis Bioceuticals and Gelteq.
Most Genetic Technologies public comparables operate across Biopharmaceuticals, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 31.4x | — | (4.0x) | — | |||
| 0.6x | 1.0x | (0.1x) | — | |||
| 1184.2x | 1184.2x | (0.2x) | — | |||
| — | — | 0.0x | — | |||
| — | — | 0.5x | — | |||
| 0.5x | — | 5.3x | — | |||
| 1.0x | — | (2.0x) | — | |||
| — | — | — | — | |||
This data is available for Pro users. Sign up to see all Genetic Technologies competitors and their valuation data. Start Free Trial | ||||||
Genetic Technologies M&A Activity
Genetic Technologies has acquired 1 company to date.
Last acquisition by Genetic Technologies was on July 19th 2021. Genetic Technologies acquired EasyDNA for $4M (EV/Revenue multiple of ).
Latest Acquisitions by Genetic Technologies
| Description | EasyDNA is a London-headquartered genetic testing laboratory with operations across the United States through partnerships with medical clinics and practitioners. The company delivers direct-to-consumer DNA tests for paternity, health, ancestry, and wellness, processing samples via accredited labs in ISO 17025-certified facilities. |
| HQ Country | |
| HQ City | Pittsburgh, PA |
| Deal Date | 19 Jul 2021 |
| Valuation | $4M |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Genetic Technologies acquisitions and their M&A valuation multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Genetic Technologies
| When was Genetic Technologies founded? | Genetic Technologies was founded in 1987. |
| Where is Genetic Technologies headquartered? | Genetic Technologies is headquartered in Australia. |
| How many employees does Genetic Technologies have? | As of today, Genetic Technologies has over 58 employees. |
| Is Genetic Technologies publicly listed? | Yes, Genetic Technologies is a public company listed on Stuttgart Stock Exchange. |
| What is the stock symbol of Genetic Technologies? | Genetic Technologies trades under DU8 ticker. |
| When did Genetic Technologies go public? | Genetic Technologies went public in 2002. |
| Who are competitors of Genetic Technologies? | Genetic Technologies main competitors include Strategic Partners, Geovax Labs, Opthea, Akari Therapeutics, Reviva Pharmaceuticals, JFL Life Sciences, Newbury Pharmaceuticals, Institute of Biomedical, Abattis Bioceuticals, Gelteq. |
| What is the current market cap of Genetic Technologies? | Genetic Technologies' current market cap is $4M. |
| What is the current revenue of Genetic Technologies? | Genetic Technologies' last fiscal year revenue is $6M. |
| What is the current EV/Revenue multiple of Genetic Technologies? | Current revenue multiple of Genetic Technologies is 0.7x. |
| Is Genetic Technologies profitable? | No, Genetic Technologies is not profitable. |
| How many companies Genetic Technologies has acquired to date? | As of May 2026, Genetic Technologies has acquired 1 company. |
| What was the largest acquisition by Genetic Technologies? | $4M acquisition of EasyDNA on 19th July 2021 was the largest M&A Genetic Technologies has done to date. |
| What companies Genetic Technologies acquired? | Genetic Technologies acquired EasyDNA. |
| In how many companies Genetic Technologies has invested to date? | Genetic Technologies hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Genetic Technologies
Lists including Genetic Technologies
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.
